Johnson & Johnson to Pay More Than $2.2 Billion to Resolve Criminal and Civil Investigations

November 2013

A press release for the Department of Justice announces “Global healthcare giant Johnson & Johnson (J&J) and its subsidiaries will pay more than $2.2 billion to resolve criminal and civil liability arising from allegations relating to the prescription drugs Risperdal, Invega and Natrecor, including promotion for uses not approved as safe and effective by the Food and Drug Administration (FDA) and payment of kickbacks to physicians and to the nation’s largest long-term care pharmacy provider.”